Rebecca Napier, MD
Advanced Heart Failure and Transplant Cardiology · Columbia, SCNPI 1730317314
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,764 of the $12,212 with a category attached, or 88.1%. 30 manufacturers reported payments, led by Abbott at 33.5% of the total. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in SC, where the typical reported total is $13,902.
Across 520 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Novartis$1K
- Alnylam Pharmaceuticals Inc.$899
- AstraZeneca$700
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$699
- Boston Scientific$666
- plus $4K from 24 others
Across 33 payments — averaging $6747.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$194K
- Novartis$29K
What the payments were for
- Consulting fees$1,44012%
- Food & beverage$10,76488%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 135 | $4,087 |
| Novartis | 73 | $1,059 |
| Alnylam Pharmaceuticals Inc. | 48 | $899 |
| AstraZeneca | 27 | $700 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 42 | $699 |
| Boston Scientific | 30 | $666 |
| Pfizer | 22 | $514 |
| Actelion Pharmaceuticals US, Inc. | 27 | $470 |
| Merck | 19 | $452 |
| Cvrx, Inc. | 9 | $348 |
| Boehringer Ingelheim | 18 | $341 |
| E.r. Squibb & Sons, L.L.C. | 14 | $313 |
| Bayer | 13 | $235 |
| Philips North America LLC | 2 | $223 |
| Lexicon Pharmaceuticals, Inc. | 2 | $139 |
| Abiomed | 2 | $134 |
| Impulse Dynamics (USA) Inc. | 1 | $127 |
| Edwards Lifesciences | 1 | $121 |
| Novo Nordisk | 6 | $120 |
| Scpharmaceuticals Inc. | 6 | $104 |
| Medtronic(2 entities) | 5 | $96 |
| Daiichi Sankyo Inc. | 4 | $81 |
| Johnson & Johnson | 6 | $74 |
| Ancora Heart, Inc. | 1 | $49 |
| Nuwellis, Inc. | 1 | $45 |
| Bridgebio Pharma, Inc. | 1 | $32 |
| Livanova USA, Inc. | 2 | $28 |
| Recor Medical Inc | 1 | $25 |
| Endotronix, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate 3 Left Ventricular Dev$1,440
- OPTIMIZER$254
- ENTRESTO$250
- FARXIGA$209
- MitraClip System$191
- Barostim Neo System$179
- (5044) MCOT$148
- CardioMEMS HF System$133
- JETI$123
- Inpefa$122
- EVOQUE$121
- WINREVAIR$115
- Impella$107
How this compares
$12,212 in reported general payments places this provider in the 45th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
See all advanced heart failure and transplant cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 70 | $1,480,159 |
| EntrestoSacubitril/Valsartan | 306 | $288,630 |
| JardianceEmpagliflozin | 155 | $164,091 |
| FarxigaDapagliflozin Propanediol | 149 | $130,671 |
| EliquisApixaban | 103 | $81,775 |
| XareltoRivaroxaban | 17 | $15,965 |
| Ranolazine ErRanolazine | 12 | $2,560 |
| Metoprolol Succinate | 213 | $2,418 |
| Bumetanide | 86 | $2,026 |
| Spironolactone | 265 | $1,539 |
| Valsartan | 59 | $1,375 |
| Atorvastatin Calcium | 77 | $1,349 |
| Carvedilol | 111 | $763 |
| Potassium Chloride | 22 | $606 |
| Rosuvastatin Calcium | 23 | $576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $514 | $1,561,935173 claims |
| NovartisEntresto | $1,059 | $288,630306 claims |
| Boehringer IngelheimJardiance | $341 | $164,091155 claims |
| AstraZenecaFarxiga | $700 | $130,671149 claims |
| Johnson & JohnsonXarelto | $74 | $15,96517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
Other advanced heart failure and transplant cardiology in Columbia
- Patrick McCannColumbia$579K
- James AmpaduColumbia$131K
- Cassandra Buto-CollettiColumbia$21K
- Joshua ConeyColumbia$14K
- Barry FeldmanColumbia$12K
- Michael RofaelColumbia$11K
- Ryan TedfordCharleston$528K
- Michael ZileCharleston$358K
- Anil PurohitWest Columbia$172K
- Daniel JudgeCharleston$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.